Brown, Lisle/Cummings, Inc. Amgen Inc Transaction History

Brown, Lisle/Cummings, Inc.

$307 Billion
Q2 2024

A detailed history of Brown, Lisle/Cummings, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 22,207 shares of AMGN stock, worth $7.1 Million. This represents 2.26% of its overall portfolio holdings.

Number of Shares

22,207

Previous 22,607 1.77%

Holding current value

$7.1 Million

Previous $6.43 Billion 7.95%

% of portfolio

2.26%

Previous 2.18%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 17, 2024	SELL	$262.75 - $319.31 $105,100 - $127,724	-400 Reduced 1.77%	22,207 $6.94 Billion
Q1 2024 Jun 28, 2024	SELL	$268.87 - $324.56 $73,939 - $89,254	-275 Reduced 1.2%	22,607 $6.43 Billion
Q4 2023 Jun 28, 2024	BUY	$255.7 - $288.46 $222,459 - $250,960	870 Added 3.95%	22,882 $6.59 Billion
Q3 2023 Jun 28, 2024	BUY	$218.65 - $271.46 $155,241 - $192,736	710 Added 3.33%	22,012 $5.92 Billion
Q2 2023 Jun 28, 2024	BUY	$214.27 - $253.37 $551,316 - $651,921	2,573 Added 13.74%	21,302 $4.73 Billion
Q1 2023 Jun 28, 2024	BUY	$225.79 - $275.2 $16,934 - $20,640	75 Added 0.4%	18,729 $4.53 Billion
Q4 2022 Jun 28, 2024	BUY	$229.03 - $291.01 $7,557 - $9,603	33 Added 0.18%	18,654 $4.9 Billion
Q3 2022 Jun 28, 2024	SELL	$224.46 - $253.15 $28,057 - $31,643	-125 Reduced 0.67%	18,621 $4.2 Billion
Q2 2022 Jun 28, 2024	SELL	$230.71 - $256.74 $29,992 - $33,376	-130 Reduced 0.69%	18,746 $4.56 Billion
Q1 2022 Jun 28, 2024	BUY	$219.27 - $242.57 $391,396 - $432,987	1,785 Added 10.44%	18,876 $4.56 Billion
Q4 2021 Jun 28, 2024	BUY	$198.88 - $227.6 $3.4 Million - $3.89 Million	17,091 New	17,091 $3.84 Billion

Others Institutions Holding AMGN

# of Institutions

3,055

Shares Held

409M

Call Options Held

7.19M

Put Options Held

6.26M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $171B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown, Lisle/Cummings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brown, Lisle/Cummings, Inc. with notifications on news.

Account

Brown, Lisle/Cummings, Inc. Amgen Inc Transaction History